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Abstract: Diagnosis of leprosy and tuberculosis in archaeological material is most informative when
based upon entire genomes. Ancient DNA (aDNA) is often degraded but amplification of specific
fragments also provides reliable diagnoses. Cell wall lipid biomarkers can distinguish ancient leprosy
from tuberculosis and DNA extraction residues can be utilized. The diagnostic power of combined
aDNA and lipid biomarkers is illustrated by key cases of ancient leprosy and/or tuberculosis.
Human tuberculosis was demonstrated in a woman and child from Atlit-Yam (~9 ka) in the Eastern
Mediterranean and in the 600 BCE Egyptian “Granville” mummy. Both aDNA and lipids confirmed
Pleistocene tuberculosis in a ~17 ka bison from Natural Trap Cave, Wyoming. Leprosy is exemplified
by cases from Winchester (10th–12th centuries CE) and Great Chesterford (5th–6th centuries CE).
A mixed infection from Kiskundorozsma, Hungary (7th century CE) allowed lipid biomarkers to
assess the relative load of leprosy and tuberculosis. Essential protocols for aDNA amplification and
analysis of mycolic, mycolipenic, mycocerosic acid, and phthiocerol lipid biomarkers are summarized.
Diagnoses of ancient mycobacterial disease can be extended beyond the reach of whole genomics
by combinations of aDNA amplification and lipid biomarkers, with sole use of the latter having the
potential to recognize even older cases.
Keywords: aDNA; cell wall lipids; evolution; genotyping; Mycobacterium leprae; Mycobacterium
tuberculosis; palaeopathology
1. Introduction
Leprosy and tuberculosis are significant global human infections today and were readily recognized
in the past. The predominant species responsible, Mycobacterium leprae and Mycobacterium tuberculosis,
are obligate human pathogens that require a living host in which to grow. Leprosy is a chronic human
infection that has declined in recent years but caused approximately 213,900 new cases in 2014 [1]
mainly in South East Asia, Africa and South America. It is a major cause of preventable disability and
of social exclusion due to stigma. M. leprae is extremely slow growing and needs to be in an intracellular
environment within a host, primarily human. Tuberculosis is an expanding global disease with an
estimated 10.4 million new cases reported in 2015 [2]. A high level of latent tuberculosis infections
suggests co-evolution of M. tuberculosis and its human host [3], at least throughout the Holocene period.
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Bacterial infections can be recognized in archaeological remains, initially by palaeopathology and
more recently by microbial ancient DNA (aDNA) [4–6]. M. leprae targets Schwann cells, damaging the
nerves, and in late infections further damage is caused by the host immune response. In lepromatous
leprosy there is a strong humeral response that is ineffective, associated with high numbers of M. leprae
bacilli. The resulting palaeopathology is typified by gross changes to the rhino-maxillary area including
pitting or perforation in the palate and resorption of the anterior nasal spine [7]. There are inflammatory
changes to the ends of the long bones plus the bones in the hands and feet due to chronic infection
from skin ulcers.
Tuberculosis is spread via infectious aerosols from the lungs of an infected person. If the bacilli
enter the blood stream or lymphatic system they can spread to all parts of the body. In rare cases this
results in skeletal tuberculosis that can be recognized by characteristic palaeopathology. It is estimated
that skeletal tuberculosis occurs in only 3–6% of tuberculosis infections [8], so the extent of tuberculosis
in historical and archaeological remains was consistently under-estimated in the past. About 50% of
these skeletal lesions involve the spine—chiefly in the thoracic and lumbar vertebrae—followed by
the cervical area and can affect one or several vertebrae. The lesions consist of circumferential lytic
areas of destruction in vertebral bodies, with minimal new bone formation. The neural arches are
rarely affected. Spinal collapse and angular kyphosis (Pott’s disease) is common [8]. Tuberculosis
may also affect other weight-bearing joints of the body such as hip or knee and can be difficult to
distinguish from other disease aetiologies. Tuberculous dactylitis (spina ventosa) can affect the hands,
particularly of younger children under six years of age. Ribs may become infected by extension from
spinal lesions, by haematogenous spread from a soft tissue focus or from direct transfer from adjacent
lung tissue [8]. Extension from the spine tends to cause destructive lesions at the head or neck of
the rib; haematogenous spread tends to result in lytic lesions with little reactive bone formation.
Diffuse periostitis or local abscess on the visceral aspects of the rib may indicate a chronic underlying
pulmonary infection, of which tuberculosis is one possibility.
A further development has been the use of organic chemical techniques to detect and identify
specific mycobacterial cell wall lipids in ancient cases of tuberculosis [9,10] and leprosy [11–13].
Indeed, these specific cell wall lipids are more stable than aDNA and have confirmed suspected cases
of ancient leprosy in the absence of M. leprae aDNA [14]. Modern genetic studies show that different
genotypes of these pathogens are found in different human populations, indicating that each species
has emerged from an evolutionary bottleneck with subsequent clonal expansion [3,15–18]. In both
these species, genotypes can be distinguished by synonymous single nucleotide polymorphisms
(SNPs) [17–19]. Strains can also be identified using variable number short tandem repeats (VNTR) [20],
spoligotyping [21] and microsatellite analysis [14], although these are often unstable due to poor DNA
repair and are thus unsuited to study deep phylogeny of the microorganism. Unique deletions and
subsets can also be exploited to identify the main lineages and branches of the M. tuberculosis (MTB)
complex that consists of all human and animal strains [15].
The growth of this field of paleomicrobiology is summarized in Table 1 for ancient
tuberculosis [4,5,9,10,22–33] and in Table 2 for ancient leprosy [6,11,14,18,34–40], highlighting the
changes in methodology over time. Detailed information for a range of studies on ancient tuberculosis
is provided in Table S1 [4,5,9,10,22–33,36,41–67]. Similarly, studies on ancient leprosy are tabulated in
Table S2 [6,11–14,18,20,34–40,53,68–76].
This review aims to introduce the techniques currently available for the identification of ancient
tuberculosis and leprosy, summarize present knowledge and discuss the validity of particular
published studies.
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Table 1. Summary of methods used in M. tuberculosis aDNA and lipid biomarker diagnoses (See
Table S1 for detailed breakdown).
Year Techniques Introduced Significance and Examples
1993–1994 aDNA fragment amplification:IS6110 123 bp and nested PCR
Proof of concept
Positive results from skeletal & tissue samples [4,5]
1995–1996
aDNA fragment amplification:
IS6110 PCR
Confirmed by Sal1 digestion
MTB aDNA found in Pre-Columbian America [22]
MTB aDNA found in bones without lesions [23]
1998–1999
Hot-start PCR IS6110, mtp40, oxyR,
spoligotyping, DNA sequencing
Mycolic acid biomarkers
M. tuberculosis specifically identified [44]
MTB cell wall mycolic acids used to confirm aDNA
findings [9,10]—significant as these are detected
directly with no amplification
2001–2003
Additional PCR markers used including
IS1081, outer & internal primers for TbD1
deletion region and spoligotyping
M. africanum found in Middle Kingdom ancient Egypt [24]
MTB genotyped in 18th cent. Hungarian natural mummies [25]
2004 PCR for canine aDNA and MTB IS6110 A 16th century Iroquoian dog had human MTB [26]
2007–2008
PCR for IS6110, IS1081, TbD1, RD
regions, oxyR285 and pncA169
Improved mycolic acid detection
First finding of Mycobacterium bovis in human skeletal remains [27]
‘Modern MTB’ in early Neolithic [28]
2012 Mycolipenic and mycocerosic acidlipid biomarkers
Specific mycolipenate and clear mycocerosate pattern confirms
MTB in ~17 ka bison [29]
2012–2016
Hybridization capture with Next
Generation Sequencing (NGS)
Metagenomics of 18th cent. MTB
Whole Genome Sequencing (WGS)
Identification of 19th cent. MTB genome [30]
Mixed MTB genomes in 18th cent. Hungarians [31–33]
Table 2. Summary of methods used in M. leprae aDNA and lipid biomarker diagnoses (see Table S2 for
detailed breakdown).
Year Techniques introduced Significance and examples
1994
aDNA fragment amplification, with
PCR primers for large target regions
(459 and 530 bp)
Proof of concept
Positive results indicate excellent M. leprae
aDNA preservation [6]
2000–2001
aDNA amplification based on specific
RLEP region
Nested & hemi-nested PCR used to target
shorter sequences
M. leprae found in 11th–12th cent.
Orkney, Scotland, UK [34]
M. leprae identified in Medieval Poland,
10th and 15th century Hungary [35]
2005 Primers devised for nested PCR for bothM. leprae aDNA and MTB IS6110
Leprosy/TB co-infections identified in the
absence of palaeopathology [36]
2006 Used hemi-nested & VNTR typing basedon repetitive sequences Different strains of M. leprae identified [37]
2009 Genotyping based on SNPsMycolic acid lipid biomarkers
SNP typing reveals human origins of
M. leprae and migrations [18]
M. leprae mycolic acids detected [11]
2012–2017 SNP sub-genotyping and WGSMycocerosic acid lipid biomarkers identified
SNP sub-genotyping elucidates geographical
differences between M. leprae from different
regions [14,38–40]
2. Methods
2.1. Extraction of Microbial aDNA
Numerous studies now confirm the possibility of extracting and amplifying microbial aDNA
from pathogens that may persist within human bones and other tissues (e.g., [6,41]). Microbial DNA
disseminated via the bloodstream may become trapped in the mineralized tissue of the skeleton, such
as hydroxyapatite, or in protected sites, such as the dental root canal and pulp chamber, where it can
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remain somewhat protected from breakdown. Authentic aDNA will eventually become degraded over
time, due to chemical processes such as hydrolytic depurination and oxidation that result in small
DNA fragments with variable degrees of damage. Mycobacterial aDNA is generally more resistant
to degradation compared to mammalian host aDNA, due to the protective presence of the bacterial
cell wall and the higher proportion of guanidine and cytosine in the DNA [77]. In DNA extraction
from human skeletal remains, bacterial aDNA may be co-purified with humic and fulmic acids that
arise from degradation of dead organic matter in soils. These are naturally occurring inhibitors of the
polymerase chain reaction (PCR) used to amplify aDNA. In addition, the breakdown products of body
fluids in human or animal remains, such as blood and bile, can inhibit PCR. Therefore, the extraction
procedure must deliver not only effective recovery of DNA fragments from a complex mixture of tissue
debris, but also ensure lysis of any remnant mycobacteria and removal of PCR inhibitors. Perusal
of the literature reveals the variety of approaches that have been used. However, the basic method
includes demineralization, DNA capture or precipitation, dehydration and elution or rehydration just
before DNA amplification.
For DNA extraction of archaeological skeletal or mummified material, an initial incubation step in
1xTris/EDTA buffer containing proteinase K solution can be performed at 55 ◦C to free cross-linkages.
Incubation can be for an hour or so, up to two to three days, with regular mixing and bead beating. Once
disrupted, a guanidium-based chaeotropic buffer, 6 M guanidium thiocyanate (GUSCN), is used for
lysis. The reagent N-phenacylthiozolium bromide (PTB) can be used to cleave any covalent cross-links,
thus enabling DNA strand separation and amplification [78]. However, PTB inhibits amplification of
highly fragmented aDNA that is directly precipitated so it can be helpful to split the sample and treat
one aliquot with 40 µL of 0.1 mol PTB followed by silica capture, with direct precipitation of aDNA in
the second aliquot without PTB. This process copes with a range of specimen types. Moreover, it is
capable of inactivating any viable mycobacteria [50], which can be an advantage in some circumstances.
Silica-based DNA extraction methods [79] have been widely evaluated and found to be most
efficient. Bouwman and Brown [80] looked at several variations of this approach for aDNA applications,
finding silica columns to be more efficient than slurries. However, slurries provide greater freedom for
incorporating additional wash steps or scaling up for larger sample volumes. If using a commercial
kit that employs columns, it must be noted that many such methods fail to efficiently recover
smaller fragments (<150 bp) of DNA although these may be typical of the pathogen aDNA found in
archaeological material.
When detection of mycobacterial aDNA is supported by lipid biomarker analysis, the latter can
be recovered from samples that have already undergone DNA extraction if required [13,38]. This is
ideal for minimizing destructive sampling or for retrospective analysis.
2.2. PCR Amplification
The amplification of aDNA requires some adjustment to the composition of the mix and the
selection of targets. Because of the possibility of residual inhibitors in DNA extracts, it is helpful
to include bovine serum albumin (BSA) in the mix to reduce PCR inhibition [81] and to ensure the
optimal level of MgCl2 for the particular samples being amplified. A concentration of 2 mM is usually
satisfactory, but 3 mM may be needed when reporting PCR product with hydrolysis probes. In early
work on aDNA, the importance of the target size for amplification was not realized. Neither was the
difference in stability of mycobacterial aDNA compared with that of mammalian aDNA appreciated.
The lipid-rich mycobacterial cell wall enabled larger DNA target regions to be used successfully in
early studies. Indeed, the first report of M. leprae aDNA used the 36-kDa-antigen gene with 530 bp as
the target sequence size [6]. A later recommendation for PCR of aDNA material was that amplicon size
should be kept below 200 bp [82]. Over the years, experience has since shown that many positive cases
would have been missed when the amplicon targeted was greater than 150 bp. Generally, ‘the smaller
the better’ is the rule for aDNA work. There are practical lower limits for amplicon size, as specificity
and ease of authentication are important considerations. Initially, conventional PCR was used and the
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amplicons identified by agarose gel electrophoresis. Restriction enzyme digestion and cloning were
also used in early studies, followed by sequencing of PCR products. Subsequently, Real Time PCR was
used with fluorescent probes, which allows far shorter target sequences to be used. Amplicons in the
range 90–120 bp remain practical as they still allow conventional sequencing to confirm identity and
also sequencing of SNPs without the need for cloning.
Repetitive elements in genomes make good targets for aDNA PCR as the chances of detecting the
pathogen template increases accordingly. Examples are the RLEP, REPLEP and LEPREP elements of
M. leprae and IS6110 and IS1081 elements of M. tuberculosis complex mycobacteria. Another good target
locus for detecting and simultaneously typing mycobacteria is the direct repeat (DR) locus, a clustered
regularly interspaced, short palindromic repeat (CRISPR/cas9) unit in the MTB complex, with its
multiple copies of inverted repeats. Any of these can be combined with a labeled hybridization probe
for reporting product with specificity and convenience. An example is shown in Figure 1, generated
from a medieval period case of lepromatous leprosy from Winchester skeleton 45 (Sk45). This shows
the RLEP product amplified from the hand (blue trace) and a tibia (red trace) [G.M. Taylor, unpublished
observation].
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Figure 1. Real Time polymerase chain reaction (PCR) amplification profiles for a medieval period 
case of lepromatous leprosy (Sk45) obtained using the RLEP PCR method with product reported 
with a specific probe. Extracts were tested in duplicate. Product is seen amplified from the hand 
(blue traces) and tibia (red traces). Black traces represent non-template controls (water blanks). 
In an early attempt to obtain genotyping information from ancient cases of 
tuberculosis, three bone samples from two separate burials, both with evidence of 
Figure 1. Real Time poly erase chain reaction (PCR) amplification profiles for a medieval period case
of lepromatous leprosy (Sk45) obtained using the RLEP PCR method wit product rep rted with a
specific probe. Extracts were test d in duplicate. Produc is seen amplified from the hand (blue traces)
and tibia (red traces). Black traces represent non-template controls (water blanks).
In an early attempt to obtain genotyping information from ancient cases of tuberculosis, three bone
samples from two separate burials, both with evidence of typical skeletal lesions, were examined [44].
These inhumations came from the cemetery site of the abbey of St. Mary Graces, on the old Royal
Mint site in London, UK and were dated broadly between 1350–1538 CE, the time the cemetery was in
use. One of the loci examined was for the rpoB gene [83] using a commercially available Inno-Lipa
Rif TB kit from Innogenetics in Belgium. This kit, used in clinical diagnostics of tuberculosis, proved
very useful for confirmation of the disease in these remains. The test strips have an oligonucleotide
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primer specific for templates from the MTB complex, which quickly identifies/eliminates those cases
where the amplicon product originates from environmental organisms other than MTB complex. The
paper also describes the first use of spoligotyping [21], to examine the DR locus, and the presence
of the mtp40 gene–although this is now known not to be conclusive proof of species as it may be
lost in some strains of M. tuberculosis as part of a deletion event analogous to RD5 of M. bovis. Also,
amplification and Sanger sequencing of the oxyR pseudogene was undertaken to determine species.
Finally, PCR based on an M. bovis specific fragment, now known to be targeting the RvD1-Rv2031c
region, was performed. In both individuals, disease was shown to be due to M. tuberculosis rather than
M. bovis. The spoligotypes obtained appeared to be identical and were again indicative of the human
pathogen. The very same methods were later applied to nine cases of tuberculosis from a rural setting,
the deserted medieval village of Wharram Percy, Yorkshire, UK [84]. At the outset of the study it was
envisaged that this would very likely provide evidence of M. bovis infection in humans, given the close
proximity of medieval farmers to their cattle. However, in six of the cases that provided genotyping
data, M. tuberculosis was found to be responsible for the observed lesions.
The occurrence of deletions in a pathogen genome can be exploited to design extremely specific
PCR methods with primers flanking the deletion and reporter fluorophores or a probe hybridizing over
the deletion breakpoint. We have used this approach to distinguish between modern and ancestral
strains of tuberculosis, by looking for the occurrence of deletion TbD1 [28,50] and the demonstration
of bovine strains in nomadic pastoralists who had contacted this disease from their herd animals [27].
In the two examples of M. tuberculosis above, of an Iron Age male individual from Dorset, UK with
suspected Pott’s disease and a woman and infant from the 9000-year-old Neolithic site of Atlit Yam
in the Eastern Mediterranean, the strains of M. tuberculosis had clearly already lost the TbD1 region.
Therefore, so-called ‘modern’ TB strains are already of some antiquity. The Atlit Yam cases were also
subjected to mycobacterial lipid biomarker analysis (see Section 3.2).
In the example of Iron Age nomadic pastoralists from Tuva, Southern Siberia [27], the primers used
flanked the RD4 deletion, an event that has come to define classic M. bovis disease found in modern
herd breakdowns. Another deletion PCR method applied in this study was for RD17, which showed
that this event had not occurred, indicating the causative strains could have been due to M. bovis a-c
lineages, but not M. bovis lineage d [85]. Two of these five cases infected with M. bovis were found in
individuals radiocarbon dated to between the 4th to 2nd centuries BCE and the remaining three to
between the 2nd to 4th centuries CE. The first two individuals therefore stem from the transition period
between the Uyuk and Shurmak Cultures and the latter three to the Shurmak or Synnchyurek Cultures.
The study of deletions in strains from dated remains can provide limits termini ante quem—dates
before which the deletion of interest, e.g., TbD1, had occurred. Slowly, this work is beginning to
provide a timeline to anchor evolutionary models of the MTB complex. The use of deletion-based
PCR overcomes the problems mentioned above in relation to specificity of the mtp40 and the ‘M. bovis
specific’ fragments, which are now both known to lie within possible deletion regions (RD5 and
RvD1-Rv2031c, respectively), so that some strains of M. tuberculosis and M. bovis will have lost these
targets, confounding the outcomes.
Ancient DNA studies have also benefited from advances in hardware and the availability of core
commercial kits for convenience, uniformity and the options for hot-start PCR. A kit employing a
hot start Taq polymerase is preferred for specificity when amplifying targets from a complex milieu,
which will invariably contain environmental bacteria. There is rarely any need for second rounds of
amplification if the initial PCR method is fully optimized. Kits with non-acetylated BSA are extremely
useful for counteracting PCR inhibitors or it can be added to in-house reaction mixes (1 µg/mL)
without reducing reaction efficiency. The typical small aDNA PCR products may be analyzed on 3% or
4% gel electrophoresis gels with appropriate size markers. However, Real Time platforms have almost
eliminated this requirement, as dissociation curve analysis and monitoring of products with labeled
hybridization probes are valuable for immediate assessment of specificity. Electrophoresis gels remain
useful for checking new methods and purifying amplicons for sequencing.
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2.3. Diversity at Multiple Locus Variable Nucleotide Tandem Repeats (VNTRs)
A number of other loci within the genomes of both M. leprae and the MTB complex species
exhibit variability. One important class consists of the short tandem repeat units—minisatellites and
microsatellites—found in M. leprae [86,87]. Equivalent sites are known within M. tuberculosis and
other complex members and have been used in standardized mycobacterial interspersed repetitive
units (MIRU) VNTR typing protocols [88] and exact tandem repeats (ETR A–D) for M. bovis [89].
Variation at these loci arises as a result of errors in replication, such as slip-strand mispairing [90]. Such
polymorphic loci have limited use for deep phylogeny as they change relatively rapidly, but we have
found them valuable for differentiating between strains with the same main genotype. For example, we
routinely use three such loci, one minisatellite and two microsatellite regions to distinguish between
strains of M. leprae [20,38]. In more than a decade of typing M. leprae strains, we have only ever
encountered the same pattern once and these were from isolates of M. leprae from the medieval
leprosarium at Winchester, UK (Sks 8 and 14, see Table 3). Radiocarbon dating showed these individuals
were near contemporaneous and the genetic analysis, following WGS, confirmed that the isolates were
very closely related [74].
Table 3. Variable number short tandem repeats (VNTR) Sub-genotyping of M. leprae aDNA.
Burial Region Century CE (AGA) 20 (GTA) 9 21-3 Type
Sk2 Winchester, UK 10th–12th 11 8 2 3I
Sk7 “ “ 13 8 2 3I
Sk8 “ “ 14 8 2 2F
Sk14 “ “ 14 8 2 2F
Sk19 “ “ 14 7 Fail 3I
Sk27 “ 11th 12 7 2 2F
G708 Yorkshire, UK 10th–12th 10 8 3 3
GC96 Essex, UK 5th–6th 14 6 2 3I
1914 Ipswich, UK 13th–15th 12 9 2 3I
Uzbek Uzbekistan 1st–4th 22 9 2 3L
KD271 Hungary 7th 16 24 2 3K
503 Hungary 10th–11th 18 8 2 3K
222 Hungary 10th–11th 12 12 2 3K
KK02 Turkey 8th–9th 12 11 2 3K
188 Czech Republic 9th 11 7 2 3M
2.4. Validation and the Use of Real Time Platforms
A number of criteria have arisen over the years for checking the authenticity of aDNA findings.
These are summarized in Table 4. For a full consideration of authentication criteria see Taylor 2014 [91].
Real Time PCR platforms have a number of advantages for routine testing of aDNA extracts and a
number of areas of synergism overlap with validation options. These, and the benefits of Real Time
instruments, are included in Table 4.
Table 4. Validation of aDNA data.
Criteria Option 1 Option 2 Option 3
Reproducibility Run in-batch replicates Run repeat assays Run repeat extracts
Independent
replication
Different operators
(in-house)
Second centre
replication -
PCR specificity Check Tm of melt curveand size on gel
Amplicon reported
by specific probes
Amplicon
sequencing
Cloning of
amplicons
Cloning & sequencing
to assess damage or
miscoding changes
- -
Appropriate
molecular behaviour
Degraded templates
Assess upper size limit
aDNA tends to high Cq
values on
real time platforms
Genotyping data should
make phylogenetic sense
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Table 4. Cont.
Criteria Option 1 Option 2 Option 3
Controls Extraction blanks totest reagents
PCR template blanks
(water)
Burials lacking lesions
& soil samples
Genotyping SNP/deletion typing VNTR analysis
NGS with controls to
judge environmental
contribution
Quantitative PCR Assess aDNA at sites both withand without lesions - -
Independent
biomarkers of disease Mycobacterial lipid biomarkers
Recovery of
peptides/proteins/sugars -
Analysis of
associated remains
Animal remains for evidence of
pathogen diseases
Animal remains for
evidence of faunal DNA -
2.5. Benefits of Real Time Platforms
2.5.1. Optimization
Real Time platforms provide rapid and visible feedback for the PCR optimization matrix
components (e.g., magnesium ion concentration, annealing temperature, and primer concentration).
For a 100% efficient PCR reaction, there should be around 3.3 cycles difference between 10-fold template
concentrations. The presence of primer-dimer will be shown by melt analysis, performed at the end of
the run and can be tuned out if required by acquiring data at a higher temperature during the run.
2.5.2. Reproducibility
Product formation from replicates can be monitored easily and cheaply in real time with intercalating
dyes such as EVA®Green. These are easily added to any PCR method and are inexpensive to use.
The specificity of products can be checked with dissociation curves (melt temperature analysis) at the end
of the run and can be tuned out if required by acquiring data at a higher temperature during the run.
2.5.3. Control Amplifications
Multiple water blanks can be included in the reaction and monitored in real time to check for any
evidence of random cross-contamination. Melt analysis will reveal the lower melting temperature
(Tm) of any primer-dimer compared to the target PCR amplicon. Alternatively, a probe can be used or
the machine software can be set to acquire data above the Tm of non-specific products, so that these
smaller molecules do not contribute to the real time amplification profile. As with conventional PCR,
primer-dimer formation is a useful indicator that inhibition was not a significant factor in a negative
result. There is seldom any need to include a positive control in an optimized aDNA PCR.
2.5.4. Assessing Inhibition
To rule out false negative results due to PCR inhibition, an internal control (IC) assay can be
multiplexed with the locus of interest. In the competitive IC model using an artificial template, this
contains the same primer annealing regions as the PCR target but with a different intermediate sequence.
Amplification of this construct is monitored with a second probe designed to the central region and
tagged with a different fluorophore. Alternatively, ‘spiking’ of unrelated PCRs with a constant amount
of extracted template can help identify inhibition due to an increase in the quantification cycle (Cq)
in affected samples, compared to the control Cq determined from spiking with water only. The Cq is
defined as the cycle number at which fluorescence first increases above a defined threshold level.
2.5.5. Validation
Genuine aDNA positives tend to have higher Cq values and product is typically seen after more
than 30 cycles of amplification, although strong positives are sometimes found. The screening PCRs we
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use for M. leprae and MTB complex mycobacteria have been well characterized over the years and the
products have been sequenced on a number of occasions. Increasingly we use specific hybridization
probes that report only the amplicon of interest. Use of a short product (60–90 bp) can effectively
corroborate product identity. Multiple polymorphic loci, amplified in the course of projects, are always
sequenced to determine genotype.
3. Mycobacterial Lipid Biomarkers
3.1. Extraction of Mycobacterial Cell Wall Lipids
Mycobacteria, including M. tuberculosis and M. leprae have hydrophobic lipid-rich cell envelopes
that express unusual lipids exploitable as specific biomarkers for their respective diseases. The lipid
classes evaluated so far, for the diagnosis of leprosy and tuberculosis, comprise mycolic, mycocerosic
and mycolipenic acids with lesser use of members of the phthiocerol family (Figure 2).
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(A) Mycolic acids, occurring as characteristic homologous types; (B) Mycolipenic acid, restricted to
the M. tuberculosis complex; (C) Mycocerosic acids, with C34 being particularly diagnostic for leprosy
(m/z 507, for example, represents the ions observed on GC-MS); (D) Phthiocerol family, with distinct
size difference between MTB and leprosy.
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The characteristic lipid components (Figure 2) of the cell envelopes of M. tuberculosis and M. leprae
are particularly suited for use as disease biomarkers as they are very distinct from all types of mammalian
lipids. The 70–90 carbon mycolic acids (Figure 2A) are fatty acids that are four to five times larger than those
in mammals that do not generally exceed 20 carbons. Similarly, the 27–34 carbon multi-methyl branched
mycolipenic (Figure 2B) and mycocerosic (Figure 2C) acids are readily distinguished. The 29–36 carbon
members of the phthiocerol family (Figure 2D) are very distinct mycobacterial biomarkers with no human
or animal equivalents. Careful scrutiny of Figure 2 reveals differential distribution of the particular
lipid moieties expressed in M. tuberculosis and M. leprae so that there is the potential to distinguish both
diseases, even when they occur in the same specimen. Methods for the exploitation of lipid biomarkers
are described below, together with examples that demonstrate their potential.
Initial detection of tuberculosis in archaeological material made use of fluorescence high performance
liquid chromatography (HPLC) of anthrylmethyl esters of mycolic acids [9,10,92]. However, the relative
instability of these derivatives dictated an alternative approach. An integrated extraction protocol
was devised for the extraction of lipid biomarkers and capture of the long-chain acid components as
pentafluorobenzyl (PFB) esters [28,29,54]. This allows the analysis of medium-chain C24–C34 mycolipenic
and mycocerosic acid PFB esters by highly sensitive negative ion chemical ionization (NI-CI) gas
chromatography mass spectroscopy (GC-MS) [54]. Stable pyrenebutyric acid (PBA) esters of mycolic
acid PFB esters and phthiocerols are prepared (Figure 2) and profiled by fluorescence HPLC using
combinations in reverse and normal phase modes [28,29]. Diagnostic certainty can depend on the relative
preservation of the particular lipid biomarker classes. If aDNA extraction does not involve organic
solvents, lipid biomarkers can be extracted from the residual material [13]. In an isolated Neolithic
case, it was possible to characterize MTB mycolic acids by direct mass spectroscopy [63].
3.2. Combined Biomarker Diagnoses—aDNA and Bacterial Cell Wall Lipids
In a pioneering study, detailed mycolic acid profiles, typical of M. tuberculosis, supported aDNA
fragment amplification to diagnose tuberculosis in ribs from a 1000-year-old skeleton from Addingham,
Yorkshire, UK [10]. Similarly, mycolic acids helped confirm tuberculosis in 1400-year-old calcified
pleural material from a Byzantine basilica in the Negev desert at Karkur, Israel [9]. A landmark study
diagnosed tuberculosis in a ~9 ka woman and child from Atlit-Yam in the Eastern Mediterranean [28].
Distinctive rib lesions were supported by amplification of aDNA and excellent profiles of mycolic and
mycocerosic acids [29,66]. The best Atlit-Yam lipid biomarker correlation is shown in Figure 3.
A challenging case was that of “Dr Granville’s Egyptian mummy” whose remains are in the British
Museum [55]. Resins employed in the mummification process hindered DNA extraction. Nevertheless,
M. tuberculosis complex DNA was obtained from lung tissue and gall bladder samples, based on
nested PCR of the IS6110 locus. These findings were supported by very good specific M. tuberculosis
complex cell-wall mycolic acid profiles from lung and femurs demonstrated by HPLC of pyrenebutyric
acid–pentafluorobenzyl mycolates. Disseminated tuberculosis may have contributed to the death of
the mummified subject. Profiles for Granville mummy femur are illustrated in Figure 4.
Another condition in which combined analyses has proven useful is hypertrophic pulmonary
osteoarthropathy (HPO). HPO can be either primary (3% of cases) or more usually secondary to
pulmonary, cardiac or abdominal diseases. It is often associated with cancer e.g., brochiogenic tumor,
Hodgkin’s disease or abdominal neoplasm, but other chronic conditions, such as emphysema, liver
cirrhosis or inflammatory bowel disease can lead to HPO. This syndrome consists of clubbing of the
digits of the hands and feet, joint inflammation and diffuse sub-periosteal bone deposition. Digital
clubbing and joint changes generally involve soft tissue only, so palaeopathological diagnosis of the
condition normally depends on the pattern and nature of sub-periosteal bone deposition. The condition
is recognized by a diffuse periostitis affecting long bones of the skeleton, distributed in a symmetrical
manner [8]. The exact etiology of this condition remains unknown, but is believed to be due to
disruption of the ability of the pulmonary capillary bed to degrade circulating factors such as vascular
endothelial and platelet derived growth factors.
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phase; (D) Collected methoxymycolates, reverse phase; (E) Collected ketomycolates, reverse phase.
Comments: Excellent MTB MA profiles. Verdict: Clear MTB.
An earlier aDNA study, of two cases of HPO from the medieval period (10th–16th century),
revealed that infection with M. tuberculosis was a likely cause of the condition in one of these individuals,
burial EE062 excavated from Wharram Percy [46]. Some years later, the opportunity arose to study a
far earlier example of HPO in the 7000-year-old skeleton of a young male individual, body HGO-53,
from the Hungarian site of Hódmezövásárhely-Gorzsa. Here, the skeleton presented a case of HPO,
with strikingly symmetrical diffuse periostitis on the long bones accompanied with rib changes
and cavitations in the vertebral bodies. The palaeopathological diagnosis was HPO secondary to
tuberculosis. This was confirmed by aDNA and cell wall lipid analysis. Three of the five skeletons with
bone lesions from this site gave supportive weak mycolic acid traces and aDNA, but only HGO-53
was positive in all three biomarker categories, namely mycocerosic and mycolipenic acid derivatives
plus IS1081 PCR [67]. This is a good example of how combinations of different biomarkers can point to
a clear consensus that tuberculosis was prevalent in the population under consideration.
In a study of 12 diverse samples from the 10th–19th centuries CE, positive aDNA amplification
indicated tuberculosis, leprosy and co-infected cases. However, mycolic acid biomarkers were often
quite degraded and discrimination between the various disease conditions was not so evident [12]. In a
more extensive survey of twenty 8th century CE skeletons from Bélmegyer-Csömöki domb, Hungary,
evidence for M. tuberculosis complex aDNA was found in five graves only [75]. Mycolic acid biomarkers
were absent in five cases, and the weak, degraded profiles for the remainder were inconclusive for either
tuberculosis or leprosy. The most positive lipid biomarker evidence for tuberculosis was provided
by mycolipenic acid, with 13 clear cases, supported by five weaker possible cases. Combinations
of mycocerosic acids were present in all but three graves and in one case a tuberculosis-leprosy
co-infection was indicated. Two specimens with pathology gave no lipid biomarker evidence, but one
of these provided M. tuberculosis complex DNA fragments. Again, taking together the overall findings,
clear evidence of tuberculosis and some leprosy was provided, even though there were no perfect
individual cases.
The best evidence for the oldest Homo sapiens TB is contained in the ~9 ka Atlit-Yam skeletons
(Figure 3), but older cases from the pre-animal domestication phase—Dja’de el Mughara, Northern
Syria (10.8–10.3 ka)—and early domestication—Tell Aswad, Southern Syria, (10.2–9.6 ka)—are
evident [64]. In the former case, TB aDNA amplification was achieved for individual 483, supported
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by clear C32 mycocerosates in both a rib and a vertebra. The vertebra also had a convincing signal for
mycolipenate offering strong evidence for MTB. Three Tell Aswad fibulae were strong for mycolipenate,
weak for mycocerosates, but no aDNA fragments were amplified [64].
The oldest case of amplified aDNA, characteristic of the M. tuberculosis complex, was identified in
a metacarpal from the Pleistocene ~17 ka Bison antiquus recovered from Natural Trap Cave, Wyoming,
USA [45]. The aDNA analyses confirmed the M. tuberculosis complex, but excluded assignment to
modern M. bovis. This potentially ground breaking result required confirmatory support and this was
provided by lipid biomarkers [29]. The mycolic acid profiles were very weak but extremely strong
results were recorded for mycocerosates and particularly for mycolipenate, which is found only in
members of the M. tuberculosis complex [93]. The combination of lipid biomarkers for the ~17 ka bison
is summarized in Figure 5.
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Figure 5. Lipid biomarker profiles for biso etacarpal from Natural Trap Cave with lesions [29,66].
(A) Total mycolates, revers phase HPLC; (B) ted total mycolates, normal phase; (C) Collected
α-mycolates, r vers phase; (D) Collected methoxy yc lates, rever e phase; (E) Collected ketomycolates,
reverse phase; (F) GC-MS of mycolipenate (C27 m/z 407) and mycocerosates (C27, C29, C30, C32)
characteristic of TB; (G) Reverse phase HPLC of phthiocerol family—PA phthiocerol A, PB phthiocerol
B, PO phthiodiolone; (H) Normal phase HPLC of collected phthiocerol fraction, X–Z are unidentified.
Comments: Inconclusive degraded MA profiles, but strong mycolipenate and mycocerosates; positive
profiles of phthiocerol family and potentially diagnostic unknowns (X–Z). Verdict: Mycolipenate
decisively confirms MTB complex.
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The choice of this particular bison metacarpal was dictated by the presence of a pronounced
lesion “undermining the articular surface”. Such metapodial lesions correlate with lesions in human
tuberculosis and they are widespread in Pleistocene megafauna including a range of bovids [94]
and mastodons [95]. The key validation of the ~17 ka bison lesions, provided by the aDNA and
lipid biomarkers, opened up the possibility that tuberculosis infected many megafauna in the
Pleistocene [29,96,97].
In the search for ancient leprosy, M. leprae aDNA was amplified from skull and tibia fragments
from a female skeleton from Uzbekistan, dating to between the 1st and 4th centuries [11]. Genotyping
showed this to be a type 3 L, not previously found in archaeological samples. In support, mycolic acids
profiles from the skull specimen corresponded well with those from standard M. leprae, but only a
weak degraded profile was recovered from the tibia sample for both the α-mycolate and ketomycolate
fractions [11]. Comprehensive results were obtained for a number of skeletons recovered from St. Mary
Magdalen, situated just to the east of Winchester, UK [38]. This leprosarium is thought to have been an
early Norman foundation, established sometime between 1070 and 1090 CE. This institution survived
the Reformation in the 16th century but was used increasingly less for the care of those afflicted
with leprosy by that time. In nine excavated individuals, showing skeletal signs of leprosy from the
earlier period (10th–12th centuries CE), we were able to amplify M. leprae aDNA and in five cases the
DNA preservation was sufficient to allow detailed genotyping to be achieved, using single-nucleotide
polymorphism (SNP) and multiple locus variable number tandem repeat analysis (MLVA). Three
of these best cases (Sk2, Sk7 and Sk19) were assigned to SNP type 3I-1 and the other two (Sk8 and
Sk14) to SNP type 2F, with distinct geographical distribution. At the time this study was undertaken,
this was the first demonstration of a type 2 strain in the British Isles. Extant examples of strains
type 2F have been reported in Turkey and Iran and other type 2s in Nepal (type 2G), Ethiopia (type
2H) and Malawi (type 2E) [18]. The significant diversity of amplified aDNA is complemented by
the uniform foundation of the mycolate and mycocerosate lipid biomarker profiles that correspond
well with those of M. leprae. The power of the combined biomarker data is illustrated in Figure 6 for
representative Winchester skeleton Sk2 (type 3I-1); the mycocerosate data are unpublished (O.Y-C.
Lee, H.H.T. Wu, G.M. Taylor, K. Tucker, R. Butler, S. Roffey, P. Marter, D.E. Minnikin, G.S. Besra, G.R.
Stewart; manuscript in preparation).
This coherent research laid the basis for progression to the first full exploitation of full genomics of
ancient leprosy cases using WGS techniques [39]. Along with three Scandinavian specimens (3077 from
Sigtuna Sweden; Refshale 16 from Denmark and Jorgen 625 from Denmark), this pioneering study
included Winchester Sk2 and Sk8 and confirmed and expanded the findings initially obtained by the
conventional approaches of PCR and Sanger sequencing. The excellent preservation of aDNA at the
Winchester site, possibly assisted by the location of many burials beneath leprosaria buildings that
persisted over hundreds of years, resulted in two further whole genome retrievals in a later work,
which concentrated on the less studied, type 2F strains [74]. The prevalence of these type 2 strains here
indicates that they may have been the co-dominant at this location during the 11th century in contrast
to later European and associated North American type 3I isolates.
A particularly informative and early case is a 4th–6th century CE male skeleton from Great
Chesterford, Essex, UK. Both multi- and single copy loci from the M. leprae genome were obtained
after aDNA amplification. An ancestral variant of the type 3I-1 lineage was found [40]. Mycolic acid
profiles were somewhat degraded with no discernible signals for ketomycolates. Strong α-mycolate
traces for metatarsal and talus specimens were recorded but the main components were 2 carbons less
than that usually found for standard M. leprae. However, excellent profiles of mycocerosates typical of
M. leprae were recorded. Complementary aDNA and lipid biomarker data for a metatarsal sample
are shown in Figure 7. At present, this case of leprosy is the earliest radiocarbon dated case in Britain
confirmed by both aDNA and lipid biomarkers.
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Verdict: Certain leprosy. 
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Figure 6. Lipid biomarker profiles for Winchester leprosy specimen Sk2 [38]. (A) Total mycolates,
reverse phase HPLC; (B) Collected total mycolates (MAs), normal phase; (C) Collected α-mycolates,
reverse phase; (D) Collected ketomycolates, reverse phase; (E) GC-MS of mycocerosates (C29, C30, C32,
C33, C34) characteristic of leprosy. Comments: Excellent leprosy MA and mycocerosate profiles. Verdict:
Certain leprosy.
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profile has α-mycolates four carbons shorter than M. leprae, but good mycocerosate profile has M. 
leprae-specific C34 mycocerosate. Verdict: Most likely leprosy and not MTB. 
In an extensive survey of the spread of ancient leprosy in Europe, two 
specimens from a young adult female (18 R and 18 L), and a specimen from a 
slightly older male (144)—all from 7th century CE Vicenne, Italy—gave consistent 
but unusual mycolic acid profiles with α-mycolates that had four-fewer carbons. 
However, 18R and 18L gave clear M. leprae mycocerosate profiles, correlating with 
Figure 7. Lipid biomarker profiles for metatarsal from Great Chesterford leprosy specimen GC
96 [40]. (A) Total mycolates, reverse phase HPLC; (B) Collected total mycolates (MAs), normal phase;
(C) Collected α-mycolates, reverse phase; (D) Collected ketomycolates, reverse phase; (E) GC-MS of
mycocerosates (C29, C30, C32, C33, C34) characteristic of leprosy. Comments: Inconclusive degraded
MA profile has α-mycolates four carbons shorter than M. leprae, but good mycocerosate profile has M.
leprae- pecific C34 myc ce os te. Verdict: Mos likely leprosy and not MTB.
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In an extensive survey of the spread of ancient leprosy in Europe, two specimens from a young
adult female (18 R and 18 L), and a specimen from a slightly older male (144)—all from 7th century CE
Vicenne, Italy—gave consistent but unusual mycolic acid profiles with α-mycolates that had four-fewer
carbons. However, 18R and 18L gave clear M. leprae mycocerosate profiles, correlating with aDNA
amplification; no aDNA was recovered from specimen 144 but a weak, recognizable mycocerosate
profile was recorded [14].
In addition to defining individual ancient cases of tuberculosis and leprosy, aDNA fragment
amplification and lipid biomarker detection has excellent potential for unraveling mixed infection
cases. A particular skeleton (KD 517) from a 7th–8th century CE site at Kiskundorozsma, Hungary,
provided aDNA amplicons for both tuberculosis and leprosy [13]. Fortuitously, the key points of the
mycolate and mycocerosate profiles were clear enough to enable a rough ratio of lipid biomarkers for
tuberculosis to leprosy of 3:2 to be estimated. This is an exemplary informative case as the initial bone
pathology suggested only leprosy. The lipid biomarker results are shown in Figures 8 and 9. Joint cases
of ancient tuberculosis and leprosy have been encountered in several other studies (Table 2, Table S2).
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Figure 8. Mycolic acid profiles from is , ungary, KD 517 [13]. (A) Total mycolates,
reverse phase HPLC. (B) Collected total mycolates (MAs), normal phase; the normalized ratios of
the α-mycolates, methoxymycolates and ketomycolates, respectively, are in brackets. (C–E): Reverse
phase HPLC of collected α-mycolate, methoxymycolate and ketomycolate fractions, respectively; the
normalized ratios of ketomycolate C83 and C87 components are shown in brackets in (E). Comments:
Good total MA profile (A) and α-mycolates (C) resemble MTB, but ketomycolates (E) have a C83
component typical of M. leprae. Verdict: Major MTB with inconclusive indication of leprosy.
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megafaunal TB from Natural Trap Cave [29,45]. In both cases, initial aDNA 
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Figure 9. Mycocerosic acid GC-MS profiles from extracts of KD 517 [13] (A) KD 517. (B) M. tuberculosis.
(C) M. leprae. Comments: Good mycocerosate profile has M. leprae-specific C34 mycocerosate; a search
for mycolipenate might have helped confirm MTB. The C34 component at 27.05 min in the M. tuberculosis
standard (B) is not a mycocerosate. Verdict: Mycocerosates confirm some leprosy, but mycolate profiles
(Figure 8) show predominance of MTB.
4. The Authenticity and Validity of aDNA and Lipid Biomarkers for Ancient Tuberculosis
and Leprosy
The earliest indications of tuberculosis and leprosy were characteristic changes in bone
morphology [8,98,99]. As summarized above, the introduction of amplification of diagnostic aDNA
fragments gave immediate reinforcement of the recognition of ancient TB and leprosy (Tables 1 and 2),
thereby providing a solid foundation for the study of ancient mycobacterial disease. Confirmation of
th se diagnoses has been increasingly supported by the detection of key lipid biomarkers, p oviding
overall confidence in the published conclusions. Of particular importance were the landmark studies of
human TB from Atlit-Yam [28] and megafaunal TB from Natural Trap Cave [29,45]. In both cases, initial
aDNA amplification was conclusively reinforced by pristine lipid biomarker profiles (Figures 3 and 5).
Nevertheless, there remains a persistent undercurrent of subjective opinion that denies the validity
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of this pioneering, objectively reviewed body of work. There are examples where aDNA findings are
criticized yet strong supportive evidence from lipid biomarkers is ignored [100,101], and doubts thus
raised tend to persist, in spite of detailed published rebuttals [102,103]. Alternatively, the potential of
lipid biomarker evidence may be acknowledged [104] but the only citation is an independent review of
non-nucleotide biomarkers [105], ignoring any of the well-documented original studies [28,29,55].
Dismissal of clear combined aDNA and lipid biomarker evidence is particularly noticeable in
cases where extrapolations of genomic data point to a particular date for the most recent common
ancestor (MRCA) of TB. A very original study [32] showed that pre-Columbian TB in Peru was
due to Mycobacterium pinnepedii, probably acquired from seals. However, the authors extrapolated
limited genomic data to propose that TB was only about 6000 years old. Their overall conclusion was
interpreted to exclude all reports of ancient TB older than ~6 ka, yet no citations of such studies were
provided. Their exclusion criteria [32] are quoted below:
(1) “rate heterogeneity or horizontal gene transfer is obscuring our dating analysis, perhaps as a
result of human population expansions which increase the availability of susceptible hosts and
allow selection to operate more quickly,
(2) the pathogens identified in the earlier archaeological material are in fact not members of the
MTBC, but rather are ancestral forms that have since undergone replacements, or
(3) certain techniques for MTBC identification in archaeological material lack specificity.”
The first statement, (1) is a simple let-out clause, suggesting a possible lack of validity in the
assumptions on which their conclusions are based. Similarly, the third criterion (3) does not require
detailed comment as the “certain techniques” are not specified and the results of any such techniques
have nevertheless been peer reviewed and validly published [93,96,106].
The second criterion, (2), depends on a clear definition of what is encompassed by the MTBC
concept and some clarification is warranted. The identified 6 ka MRCA [32] may indeed be a
“replacement” but this does not mean that the strains that were replaced, did not cause tuberculosis,
and could not be included in the broad taxon labelled M. tuberculosis. The complex issue of evolving
clonal bacterial populations has been addressed in detail, as represented in Figure 10 [107].
Key pertinent guidelines from the perceptive overview of Smith et al. (2009) [107] (Figure 10) are
quoted below.
(1) “Every species has a most recent common ancestor (MRCA) that is the coalescence of all extant
lineages. The MRCA of M. tuberculosis is not necessarily the first strain of M. tuberculosis to infect
humans, and is no more than the coalescence of all extant lineages; it may have been one member
of a large population of M. tuberculosis strains (Figure 10)”.
(2) “The MRCA of M. tuberculosis, or any species, can change over time as lineages die out and the
population evolves (Figure 10). The MRCA of a population is based on the sum of all extant
strains, and if lineages become extinct then the MRCA will change. Both selective sweeps (the
replacement of all alleles in a population by a selected allele) and drift (the random loss of
lineages from a population by sampling each generation) can cause lineages to become extinct.
For example, if Beijing strains of M. tuberculosis outcompete all other extant lineages then the
MRCA of all extant M. tuberculosis strains will become a Beijing strain. This change in the MRCA
of a species is common to all organisms, but is probably more important for clonal organisms
such as M. tuberculosis, for which selective sweeps can drive whole chromosomes to fixation and
purge all variation in the population.”
(3) “M. tuberculosis may have infected humans for hundreds of thousands of years, or longer,
before the current MRCA appeared, but those ancient lineages have been lost from the present
population. Thus, molecular dating does not tell us how long humans and M. tuberculosis have
coexisted (Figure 10)”.
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A simplified interpretation of the above detailed statements is provided by reference to the
hypothetical graphical picture presented in Figure 10 [107]. The suggested MTB MRCA at ~6 ka, derived
by molecular dating [32], could correspond, for example, to the strain labelled 5© in Figure 10. However,
access to direct ancestors of mycobacteria, corresponding to point 5©, has been lost by genetic drift. Earlier
populations, represented by strain 4© are still M. tuberculosis but they may be currently inaccessible from
reference genomes, such as those used to postulate the ~6 ka MRCA [32]. As indicated in Figure 10, a
representative strain, such as 4©, could have co-existed with strain 5© and caused tuberculosis practically
up to the present day. Care must be taken, therefore, not to consider strains of evolving pathogens in
strict chronological order, as potential ancestors (e.g., 4©) of accessible strains (e.g., 5©) may not have
become immediately extinct. A possibly related informative example of this phenomenon concerns the
diverse taxon comprised of smooth tubercle bacilli, labelled “Mycobacterium canettii” [96,97]. Relatives
of “M. canettii” are likely ancestors of the MTB complex but they are occasionally isolated from current
tuberculosis patients [96,97]. It is clear, therefore, that an absolute age of ~6 ka cannot be imposed for
tubercle bacilli, as fully endorsed elsewhere in a detailed review [108]. The above arguments are also
relevant for a more recent restatement of a ~6 ka TB age limit [33].
The supposed ~6 ka TB MCRA limit has been subjectively relaxed in a recent review, but still the
authenticity of any older cases remain denied [109]. The dogmatic view continues, that anything short of
a full genome is unacceptable. This sustained subjective denial of the value of aDNA amplification [109]
also totally and conveniently ignores the solid body of lipid biomarker evidence for landmark cases,
such as the ~9ka Atlit-Yam woman and child (Figure 3) [28] and the ~17 ka bison (Figure 5) [29]. Indeed,
deliberately ignoring ancient lipid data is tacit evidence of the value of these biomarkers that are difficult
to dismiss on contamination grounds as no amplification is involved. Detection of ancient disease should
be a purely forensic operation, all evidence being admissible. All-inclusive genomic evidence may be
conclusive but failing that, a diagnostic portfolio can be assembled from combinations of established
factors, such as bone lesions, aDNA and lipid biomarkers. Combinations of evidence are then judged by
peer review and authoritative publications are added to the record. The identification of ancient leprosy
by aDNA fragment amplification, occasionally supported by lipid biomarkers, has not been subjected
to the same level of subjective scrutiny as ancient tuberculosis even though the analytical protocols
are practically identical. The power of the general approach is amply illustrated by the example of
the jointly infected specimen KD 517 where amplicons for both TB and leprosy were detected and the
non-amplified lipid profiles were clear enough to allow estimates of the bacterial load for each disease
(Figures 8 and 9).
A perspective on past investigations and future capabilities for ancient TB is illustrated in Figure 11.
Currently it is apparent that full TB genomics have only reached back a few thousand years, but aDNA
amplification of degraded fragments has allowed diagnoses of ancient disease at least to 17 ka [45].
Lipid biomarkers have also easily reached this 17 ka landmark in a bison metacarpal (Figure 5) [29].
The overall age of tuberculosis remains undefined but the limits of current techniques (Figure 11) may
be stretched and new approaches may be developed to reach even further into the past.
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In contrast, evidence for ancient leprosy does not appear to stretch back more than several
thousand years (Figure 12). The oldest skeletal indication appears to be a specimen from India, dated
at around 2000 BCE [110]. Currently, the most ancient leprosy genomes have been recovered from
mediaeval European cases [39,74]. A number of joint leprosy/MTB cases are also highlighted in
Figure 12.
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5. Conclusions
The fields of aDNA amplification and lipid biomarker analysis have been systematically
developed over the last two decades to produce significant contributions to our understanding of the
host-pathogen interactions of the ancient diseases of leprosy and tuberculosis. Both techniques assist
osteologists in the confirmation of disease in human or animal remains, particularly in incomplete
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or damaged skeletons or in the early stage of disease when lesions may be inconclusive. Thus they
may assist with differential diagnosis in situations such as lytic vertebral lesions that could be due
either to Pott’s disease of the spine or brucellosis. They can identify cases where co-infections may be
present. These techniques can document the prevalence of disease in past populations and highlight
specific links with human activity such as farming and proximity to zoonoses such as M. bovis. On
occasion, ancient DNA or lipid biomarkers can identify novel or alleged palaeopathological indicators
of disease, for example periostitic rib lesions and HPO as indicators of pulmonary tuberculosis.
The greater stability of some lipid biomarkers, such as mycolic, mycolipenic and mycocerosic acids,
increases the chances for successful detection of mycobacterial disease in older cases where aDNA
has not survived. Conventional genotyping and recent advances with WGS extend our knowledge of
the diversity and spread of both mycobacterial pathogens, at least in recent times. A consequence of
the current limited range of a few thousand years for the use of WGS (Figures 10 and 11) is that the
deep origins of tuberculosis and leprosy remain obscure. Combinations of aDNA amplification and
lipid biomarkers currently provide informative data and signposts for older sources of mycobacterial
disease, particularly for tuberculosis back into the Pleistocene epoch.
A current essential strategy, in looking for ancient tuberculosis and leprosy in archaeological
materials, should initially involve observation of any physical indications, such as bone lesions.
Circumstantial evidence, the presence of leprosaria for example, is also very important. A logical next
step would be to attempt to extract good quality aDNA to enable the production of full mycobacterial
genomes. Amplification of key aDNA fragments would be a fallback position, ideally with lipid
biomarker confirmation. Finally, lipid biomarkers alone can provide evidence for ancient tuberculosis
and/or leprosy.
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